The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Non-Linear Path of Discovery, & Publicly Funded Research

The Non-Linear Path of Discovery, & Publicly Funded Research

November 19, 2018 • By Philip Seo

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Matt Cuda / shutterstock.com

Matt Cuda / shutterstock.com

Black powder was initially developed in 9th century China, by Taoists searching for the philosopher’s stone, which fans of Harry Potter will remember is the talisman that grants eternal life. The Chinese name for black powder literally translates as fire medicine. The chemical composition of black powder was first recorded in China during the 11th century and prominently featured saltpeter, or potassium nitrate, which was a key component of many medicinal compounds at that time.1

You Might Also Like
  • The Tortured Path to the Cortisone Discovery
  • Funding Sources for Scientific Discovery, Medical Research
  • Trio Wins Chemistry Nobel for Work on Antibody Drugs & Detergents
Explore This Issue
November 2018
Also By This Author
  • The Benefits of Blood Money: OxyContin & Ethics

Soon after the composition of black powder was recorded, its raison d’être became apparent: You could set it on fire. Black powder is called a low explosive, because when it ignites, it decomposes slowly, and it creates a propulsive force at subsonic speeds, enough to propel a bullet without rupturing the barrel of a gun. And so the modern era of warfare was born.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

But that’s not the story I want to tell.

Evolution

The same features that made black powder, also known as gunpowder, effective in munitions also made it ineffective in a field far more lucrative than warfare—mining. Its low explosive force made it ineffectual at rending rock face so miners could reach the valuable minerals that lay beneath. Gunpowder was a low explosive. What the miners needed was a high explosive.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Miners would have to wait until 1847, when an Italian chemist named Ascanio Sobrero wrote a monograph on “detonating compounds” that could be produced by combining nitric acid with a number of substances, including sugar, dextrin, lactose and glycerine. Dr. Sobrero wrote, “The results that I have just obtained prove that glycerine is capable of giving, when mixed with nitric and sulfuric acids, a substance similar to gun cotton” or nitrocellulose, which was the most powerful explosive at that time.2

Dr. Sobrero actually discouraged the commercial use of nitroglycerin. In his subsequent papers, he described characterizing the properties of nitroglycerin by using just a few drops, because the compound was so unstable.3 The problem was that commercial applications, like mining, required crates—not just drops—of nitroglycerin to be transported over long distances.

The results were predictable. In 1867, the state of California banned the transport of liquid nitroglycerin.4 Other states soon followed, and eventually heavy restrictions on the transportation of nitroglycerin became commonplace.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Accidental Prize

This was a problem for a munitions company that had gradually morphed into a company specializing in the production of nitroglycerin for excavation and mining. Its profits in danger, Alfred Nobel & Company focused on developing a safer, more stable version of nitroglycerin. Mr. Nobel was the son of an inventor, and perhaps it is not surprising he figured out that by combining nitroglycerin with the diatomaceous earth that surrounded his factory in Hamburg, he was able to stabilize dynamite for transport.5 When combined with his other invention, the blasting cap, which allowed for remote detonation, it was the perfect explosive.

But that’s not the story I want to tell, either.

There is an expression that, “if you build a better mousetrap, the world will beat a path to your door.” Mr. Nobel had succeeded in building a better mousetrap. His brilliance may not have been in the invention of dynamite, however, but may have been in his aggressive defense of his patent for dynamite. If you wanted this particular mousetrap, you would have to buy it from him.

Gradually, this led to the accumulation of an enormous amount of wealth under a single person.

How did we get from there to the Nobel Prize? It may have been an accident.

In 1888, Alfred’s brother, Ludvig Nobel, died. A French journalist, thinking it was Alfred who had passed on, wrote, “le marchand de la mort est mort”—or “the merchant of death is dead.”6 Although he had not yet died, the description was otherwise accurate. Alfred Nobel continued to make large amounts of money from the sale of munitions, in addition to the sale of explosives. This weighed on him heavily, and it is said this headline, along with his brother’s passing and his own approaching mortality, made him think carefully about the legacy he wanted to leave behind.

It also may have been a bit of luck. Upon Alfred Nobel’s death, he left the majority of his wealth to the creation of a series of prizes to be awarded by the Royal Swedish Academy of Sciences, the Karolinska Institute, the Swedish Academy and the Parliament of Norway. But there were a few problems:

“The will of Alfred Nobel came as a complete surprise; he had discussed it with no one before his death. It was handwritten on a sheet of paper, with notes scribbled in the margin, and had never been reviewed by a lawyer, since Nobel distrusted lawyers. … They faced several problems:

Pages: 1 2 3 4 | Single Page

Filed Under: Opinion, Rheuminations Tagged With: Research FundingIssue: November 2018

You Might Also Like:
  • The Tortured Path to the Cortisone Discovery
  • Funding Sources for Scientific Discovery, Medical Research
  • Trio Wins Chemistry Nobel for Work on Antibody Drugs & Detergents
  • Pediatric Care, Disparity Awareness Among Rheumatology Research Foundation-Funded Studies Underway

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)